此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants (PNIRS in VLBWI)

2026年11月17日 更新者:Lizelle Van Wyk、University of Stellenbosch

Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants: a Pilot Study

This study will look at whether a monitoring method called near-infrared spectroscopy (NIRS), can help assess lung disease in premature babies.

The main aim of this study is to describe lung oxygen levels measured by NIRS in premature babies with respiratory distress syndrome (RDS) during the first 72 hours after birth. The study will include babies born at or before 32 weeks of pregnancy who need continuous positive airway pressure (CPAP) for RDS. The study will also assess whether these lung oxygen measurements can help predict which babies will need surfactant treatment, and whether they can predict which babies may need more than one dose of surfactant.

The study will also compare lung NIRS measurements with other ways of assessing breathing problems, including lung ultrasound scores and oxygen-related measurements. In addition, the researchers will compare lung oxygen measurements with brain oxygen measurements. They will also look at whether surfactant treatment changes oxygen levels in the lungs and brain. Information from routine vital signs, such as heart rate, breathing rate, and oxygen saturation, will also be studied to see whether these measurements can help predict the need for surfactant.

Added to this researchers will look at the hemodynamics of surfactant administration by seeing how the heart and blood vessels react to surfactant administration

研究概览

详细说明

Aim: To determine pulmonary regional oxygen saturation (prSO2) in preterm infants (≤32 weeks) with respiratory distress syndrome (RDS) requiring continuous positive airway pressure (CPAP) with or without surfactant replacement therapy (SRT)

Objectives:

Primary: Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life. Secondary: (1) Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS, (2) Evaluate the ability of prSO2 to predict the need for repeat surfactant administration in preterm infants with RDS, (3) Determine correlation between prSO2, lung ultrasound (LUS) scores and oxygenation indices.

Tertiary: (1) Determine the correlation between prSO2 and cerebral oxygenation (crSO2), (2) Determine the effect of surfactant administration on prSO2 and crSO2, (3) longitudinal analyses of vital signs (HR, SpO2, NIRS, oxygenation indices) to predict SRT, (4) determine the hemodynamic effects of SRT (longitudinal correlation of NIRS, haemodynamic parameters)

This will be an investigator-initiated, prospective, observational trial.

Preterm infants born at a gestational age ≤ 32 weeks will be recruited from a single neonatal center, Tygerberg Hospital, Cape Town, South Africa.

All preterm infants ≤ 32 weeks and/ or ≤1800g will be eligible for enrollment

Study Procedures

Recruitment and enrollment processes Infants will be screened within the first 3 hours after birth. Infants meeting enrollment criteria will be placed on study monitoring devices upon arrival in the neonatal unit, if meeting eligibility criteria.

Randomization/ blinding No randomization will occur in this study. Blinding is not possible due to visible monitoring equipment. Treating clinicians will however be directed not to use the monitors for any decision-making regarding patient management.

Monitoring Devices

  1. Near-infrared spectroscopy will be performed using INVOS 5100c (Medtronics, Minneapolis, MN, USA) with 2 transducers, will be used that allows monitoring of 4 regions of interest. In this study 3 regional saturations will be monitored - pulmonary (left and right) and cerebral

    • Pulmonary NIRS - Pulmonary sensors will be placed in a horizontal position at the 4th intercostal space area (nipple line) on the left and right hemithorax
    • Cerebral NIRS - Cerebral sensor will be placed on the right of the forehead
  2. Vital sign monitoring: Synchronized vital signs (heart rate (HR), respiratory rate (RR), peripheral oxygen saturation (SpO2) (Nellcor) will be monitored using a multi-parameter monitor (Mindray UMEC15, Shenzhen, China).

  3. Non-invasive cardiac output monitoring: Haemodynamic monitoring will occur using the ICON Core from Osypka Medical. This provides non-invasive monitoring of numerous haemodynamic parameters, including cardiac output, stroke volume, systemic vascular resistance, cardiac contractility and thoracic fluid content. ICON sensors will be placed in standard positions on the forehead, neck arm and leg for monitoring.

Intervention procedures

1. Ultrasound:

  1. Lung ultrasound (LUS) will be performed after placement of the NIRS (within the first 6 hours of life) and daily. LUS will also be performed prior to any SRT. alculated. Video-clips will be stored and reviewed by blinded co-investigators.
  2. Cranial ultrasound (CUS) will be performed on day 1,2 and 3 to monitor for any intraventricular haemorrhage as well as to measure cerebral blood flow velocities, which may affect crSO2 values.
  3. Point-of-care echocardiography (POC-echo) will be performed to determine cardiac function, cardiac output, and the presence of a patent ductus arteriosus, size, flow velocity and pattern, which may affect prSO2 and crSO2 values. Standard echocardiography techniques will be used and will be performed daily on day 1,2 and 3 of life.

Trial duration

The trial will start enrolling 1 November 2026 or when all procedures have been completed. Trial will be completed when 100 participants have been recruited.

Discontinuation of study intervention

Monitoring of the infant will stop, and sensors will be removed if:

  • Requested by mother
  • Requested by treating clinician
  • Thoracic intervention required (e.g. intercostal drainage for pneumothorax)
  • Surgery required (e.g. laparotomy for focal intestinal perforation)
  • Sensors interfere with medical management

Withdrawal from study

At any time point the mother or treating clinician may request withdrawal of the infant from the study, for any reason, whether for personal choice (by the mother), safety considerations or administrative reasons. Monitoring of the infant will be stopped immediately, and no further data will be collected. However, the infant will remain in the study for data analyses and outcome and clinical measure collection, unless the mother specifically requests that their infant's data not be included. Withdrawal of the infant from the study, irrespective of reason, will not influence the continued management of the infant and they will continue to receive management as per protocols in the institution.

Duration of study participation

Study participation for each infant is:

  • Initiated within the first 3 hours of life
  • Monitoring until 72 hours after birth
  • Follow up from 72 hours until final discharge from hospital or in-hospital death.

Infants who are transferred to other institutions will be followed up for length of stay as well as neonatal respiratory complications (length of respiratory support, bronchopulmonary dysplasia, death)

研究类型

观察性的

注册 (估计的)

100

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Lizelle Van Wyk, PhD
  • 电话号码:+27219389506
  • 邮箱:lizelle@sun.ac.za

学习地点

      • Cape Town、南非、7530
        • 招聘中
        • Tygerberg Hospital
        • 接触:
        • 接触:
        • 首席研究员:
          • Lizelle Van Wyk, PhD
        • 副研究员:
          • Pierre Goussard, PhD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6个月 至 7个月 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

All preterm infants 27-32 weeks born at Tygerberg Hospital, Cape Town, South Africa will be elligible for enrollment

描述

Inclusion Criteria:

  • Preterm infant ≤ 32 weeks gestational age and/ or birth weight ≤ 1800g
  • Infant diagnosed with respiratory distress syndrome requiring CPAP after birth
  • Infant born at the research institution

Exclusion Criteria:

  • Infants ≤ 26 weeks gestational age or <750g
  • Infants with other causes of respiratory distress
  • Infants with antenatal or postnatally diagnosed structural pulmonary abnormalities
  • Infants with known or suspected chromosomal abnormalities
  • Infants with other congenital structural abnormalities that may require surgery in the first 72 hours after birth
  • Infants with known or suspected congenital infections including congenital syphilis, cytomegalovirus or toxoplasmosis
  • Infants intubated after birth or requiring intubation and invasive ventilation immediately after birth
  • Infants with a 5-minute Apgar ≤ 5
  • Instillation of surfactant prior to enrollment
  • Infants not expected to survive the first 72 hours after birth

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
CPAP only

Infants receiving CPAP only

Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position

SRT

Infants receiving CPAP plus surfactant

Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
PRSO2 values
大体时间:72 hours

Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life

72 hours

次要结果测量

结果测量
措施说明
大体时间
SRT prediction
大体时间:72 hours

Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS

72 hours
Compare prSo2 & lung ultrasound between groups
大体时间:72 hours

Determine correlation between prSO2 and lung ultrasound (LUS) scores between groups

72 hours
Compare prSo2 & OSI between groups
大体时间:72 hours

Determine correlation between prSO2 and OSI between groups

72 hours
Compare prSo2 & SOPI between groups
大体时间:72hrs

Determine correlation between prSO2 and SOPI between groups

72hrs

其他结果措施

结果测量
措施说明
大体时间
PRSO2/CUS
大体时间:72hours

Determine the correlation between prSO2 and cerebral oxygenation (crSO2) between groups

72hours
Longitudinal analysis SOPI
大体时间:72 hours

longitudinal comparison of SOPI between groups

72 hours
Longitudinal OSI
大体时间:72 hours

longitudinal comparison of OSI between groups

72 hours
Longitudinal thoracic fluid content (TFC)
大体时间:72 hours

longitudinal comparison of TFC between groups

72 hours
Longitudinal CI
大体时间:72 hours

longitudinal comparison of cardiac index between groups

72 hours

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2027年12月30日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2026年5月13日

首先提交符合 QC 标准的

2026年11月17日

首次发布 (实际的)

2026年11月20日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月17日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Patient data, as per SUN HREC guidelines, can only be shared upon an agreed upon data sharing agreement

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅